MURANO, a randomized phase III study sponsored by Abbvie, showed that patients with relapsed or refractory chronic lymphocytic leukemia achieved significantly prolonged median progression-free survival with Venclexta/Venclyxto (venetoclax) in combination with Rituxan (rituximab) [median PFS, not reached], compared with bendamustine in combination with Rituxan [median PFS, 17.0 months; hazard ratio, 0.17; 95% CI, 0.11–0.25; P<0.0001].
Eating less sugar could protect the microbiome during antibiotic treatment, according to a study led by researchers at City of Hope. The study followed patients with blood cancer who were going through an intensive treatment called allogeneic hematopoietic cell transplant. This population is at particularly high risk for severe gut microbiome disruption and associated side effects.
